PER® Congress on Hematologic Malignancies (Winter Hematology®) (2024)

Indirect Comparison Study Shows PFS Superiority for Zanubrutinib vs Acalabrutinib in CLL

By Ashling Wahner

March 1st 2024An indirect comparison study in relapsed/refractory chronic lymphocytic leukemia demonstrated survival benefits with zanubrutinib vs acalabrutinib.

Resistance Mutations Present an Ongoing Challenge in Aggressive Hematologic Malignancies

By Brittany Lovely

February 28th 2023With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

Wang Details Caveats to Standards of Care for Treating Patients With MCL

By Megan Hollasch

February 28th 2023When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

New Approvals Continue to Shift Treatment Landscape in Hematologic Malignancies

By Lindsay Fischer

February 27th 2023Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

Progress in Disease Detection Sets the Stage for MRD’s Role in AML

By Brittany Lovely

February 27th 2023For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.

Davids Highlights Mounting Treatment Options in CLL

By Kyle Doherty

February 25th 2023Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

Dr. Sauter on Questions Surrounding Novel Therapies in Hematologic Malignancies

By Craig Sauter, MD

February 24th 2023Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Dr. Wang on Contraindications to Hypomethylating Therapy in Older Patients With AML

By Eunice Wang, MD

February 24th 2023Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population
See Also
Everything You Need to Know About Hematology-Oncology Fellowship Applications: Tips From Current and Incoming FellowsMy Journey Through the Hematology / Oncology Fellowship MatchGreenberger Uncovers Noteworthy Updates and Triumphs in HematologyOntology | HemOnc.org - A Hematology Oncology Wiki

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

By Brittany Lovely

February 24th 2023Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Dr. Cortes on Better Understanding Areas of Interest in ALL

By Jorge Cortes, MD

February 24th 2023Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Investigators Push to Leverage Liquid Biopsy As New Standard in Early Detection, Prognosis of Hematologic Malignancies

By Brittany Lovely

March 3rd 2022Leveraging the advances made with liquid biopsies in pantumor assays and specific hematologic cancers has laid the groundwork for the shift in care by using single, or multifaceted approaches for identifying, predicting, and monitoring disease progression.

Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML

By Kyle Doherty

February 28th 2022Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

Checkpoint Inhibitors and Bispecifics Build Momentum Throughout Lymphoma

By Caroline Seymour

February 28th 2022Although checkpoint inhibitors and bispecific antibodies have come to represent clinical oncology’s fourth leg of treatment—immunotherapy—there remains much to explore within lymphoma.

Treatment and Sequencing Options Continue to Evolve in Relapsed/Refractory DLBCL

By Chris Ryan

February 28th 2022The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.

Novel Combination Therapies Show Promise in Managing Early Relapse in Multiple Myeloma

March 2nd 2021There is building evidence that novel combination therapies could be effective in treating early relapsed multiple myeloma.

Genotyping Offers Insights Into Key Characteristics of ALL Subtypes

By Jessica Hergert

March 2nd 2021Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.

Armand Reviews Novel Therapeutics in Relapsed/Refractory Follicular Lymphoma

By Caroline Seymour

March 2nd 2021Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Investigative Interventions Gain Ground in GVHD

By Courtney Marabella

March 2nd 2021With an increased understanding of disease biology, several approaches are under examination to optimize the management of patients with graft-versus-host disease.

New Methods for MRD Testing Help to Predict Relapse Across Multiple Leukemia Subtypes

By Hayley Virgil

March 2nd 2021Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.

BR Retains its Role in Frontline Waldenström Macroglobulinemia Despite the Utility of BTK Inhibitors

By Jessica Hergert

March 1st 2021The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.

Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma

By Jason Harris

March 1st 2021Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.

A More Simplified Health Care System is Needed to Provide Value

By Denise Myshko

March 1st 2021Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.

DiNardo Describes Practical Considerations for the Management of Unfit Patients With AML

By Courtney Marabella

February 28th 2021Several options have emerged for patients with acute myeloid leukemia who are not candidates to receive chemotherapy, with venetoclax-based regimens chief among them.

Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm

By Hayley Virgil

February 27th 2021Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for Cancer Therapy

By Kristi Rosa

February 27th 2021Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.

Dr. Martin on Potential Drug-Drug Interactions With BTK Inhibitors in MCL

By Peter Martin, MD

February 26th 2021Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Raising the Standard Beyond Frontline R-CHOP in DLBCL

By Caroline Seymour

February 26th 2021Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

By Hayley Virgil

February 26th 2021CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies

By Jason Harris

February 26th 2021Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

Growing Body of Evidence Underscores the Activity and Safety of CAR T-cell Therapy in ALL

By Caroline Seymour

February 25th 2021Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.
PER® Congress on Hematologic Malignancies (Winter Hematology®) (2024)

References

Top Articles
Tabouli Recipe (Tabbouleh)
Dark Chocolate Bark with Candied Oranges - Robust Recipes
Allen ZN102 Rack Review - Flat Iron Bike
Allen Trunk Bike Rack Review: Premier, Deluxe, Ultra Compact
Nws Morgantown Wv
Lohnabrechnung online einfach gemacht | ePAYSLIP®
Boevengalerijen, beroemdheden en België: een korte geschiedenis van de "mugshot"
HPE 877758-B21 1.92TB 2.5in DS SATA-6G SC Read Intensive G9 G10 SSD
China’s banned online communities have found a new home on Reddit
Obituaries in Shelby, NC | Shelby Star
Themilarose
Stellaris finally balances The Shattered Ring origin
Latest Posts
Apple Crisp Bars Recipe
Deviled Potatoes Recipe (Vegan Deviled Eggs)
Article information

Author: Nathanael Baumbach

Last Updated:

Views: 6270

Rating: 4.4 / 5 (55 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Nathanael Baumbach

Birthday: 1998-12-02

Address: Apt. 829 751 Glover View, West Orlando, IN 22436

Phone: +901025288581

Job: Internal IT Coordinator

Hobby: Gunsmithing, Motor sports, Flying, Skiing, Hooping, Lego building, Ice skating

Introduction: My name is Nathanael Baumbach, I am a fantastic, nice, victorious, brave, healthy, cute, glorious person who loves writing and wants to share my knowledge and understanding with you.